Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
Journal of Enzyme Inhibition and Medicinal Chemistry|July 8, 2026
Evolving CRBN ligands enhance the drug-like properties of protein degradersXin-Qian Ji, Lin Wang, Xing-Jie DaiEuropean Journal of Medicinal Chemistry|February 17, 2024
Identification of the exosomal PD-L1 inhibitor to promote the PD-1 targeting therapy of gastric cancerJian-Gang Sun, Ya Gao, Yong-Shun Gao, et al.Chemical Biology & Drug Design|November 24, 2016
Synthesis, cytotoxic activity, and 2D- and 3D-QSAR studies of 19-carboxyl-modified novel isosteviol derivatives as potential anticancer agentsCong-Jun Liu, Tao Zhang, Shu-Ling Yu, et al.Journal of Medicinal Chemistry|September 15, 2020
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and PerspectiveXing-Jie Dai, Ying Liu, Xiao-Peng Xiong, et al.International Immunopharmacology|March 22, 2024
CD155 as an emerging target in tumor immunotherapyJiang-Wan Wu, Ying Liu, Xing-Jie Dai, et al.Bioorganic & Medicinal Chemistry Letters|October 26, 2016
Syntheses, cytotoxic activity evaluation and HQSAR study of 1,2,3-triazole-linked isosteviol derivatives as potential anticancer agentsCong-Jun Liu, Yan-Ping Liu, Shu-Ling Yu, et al.Bioorganic Chemistry|January 30, 2026
Decoding IL4I1: The Core role of metabolism-driven immune regulation and new perspectives on disease targetingMengzhi Zhang, Xing-Jie Dai, Binbin Huang, et al.Journal of Medicinal Chemistry|February 23, 2021
Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1Xing-Jie Dai, Ying Liu, Lei-Peng Xue, et al.European Journal of Medicinal Chemistry|March 21, 2016
Synthesis, cytotoxic activity evaluation and HQSAR study of novel isosteviol derivatives as potential anticancer agentsCong-Jun Liu, Shu-Ling Yu, Yan-Ping Liu, et al.Medicinal Research Reviews|January 21, 2025
Unleashing the Power of Covalent Drugs for Protein DegradationMeng-Jie Fu, Hang Jin, Shao-Peng Wang, et al.Pageof 3